Long-term dupilumab efficacy and safety in moderate-to-severe atopic dermatitis: A real-world single-center retrospective study.

Abstract

Real-world evidence on the long-term outcomes of dupilumab in moderate-to-severe atopic dermatitis (AD) remains limited. To evaluate the real-world efficacy and safety of dupilumab and identify factors influencing treatment response. A retrospective study of 79 AD patients treated with dupilumab from January 2022 to May 2024. Patients were categorized by response into long-term, short-term, and tapering groups. Eczema Area and Severity Index (EASI), Atopic Dermatitis Severity Score, pruritus Numeric Rating Scale, and Dermatology Life Quality Index were assessed at baseline, 16, and 52 weeks. After 16 weeks, significant improvements were observed in Atopic Dermatitis Severity Score (46.62 vs 25.22, P < .001), EASI (15.65 vs 5.94, P < .001), and pruritus Numeric Rating Scale (7.41 vs 3.73, P < .001). EASI-50 and EASI-75 response rates were 72.15% and 44.3%, respectively. The long-term group had a significantly longer mean relapse-free period (159.55 days) than the short-term (66.40) and tapering (48.17) groups. Relapse was influenced by baseline immunoglobulin E, AD subtype, and disease duration. Four self-limiting adverse events were reported, with no treatment discontinuations. The study's retrospective design and single-center sample may limit generalizability. Dupilumab is effective and safe for moderate-to-severe AD, with long-term use significantly delaying relapse.